Stay updated on REOLYSIN in KRAS Mutant CRC Clinical Trial

Sign up to get notified when there's something new on the REOLYSIN in KRAS Mutant CRC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the REOLYSIN in KRAS Mutant CRC Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Revision: v3.4.2 added; the funding-lapse notice and Revision: v3.4.1 were removed; these are site-wide updates and do not affect the study details. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T01:49:22.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A site-wide notice about a lapse in government funding and the page revision updated to v3.4.1 were added, replacing the previous revision v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2026-02-04T00:45:31.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added a glossary toggle and updated QC-related wording (Last Update Submitted that Met QC Criteria) and the revision label (Revision: v3.4.0); No FEAR Act data wording was adjusted. These are metadata/UX changes and do not modify core study content, eligibility criteria, or results.
    Difference
    0.2%
    Check dated 2026-01-27T23:44:04.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Core components such as Bevacizumab, FOLFIRI, REOLYSIN, and related eligibility/intervention terms were removed from the record, altering how the study is described and who may be eligible to participate.
    Difference
    18%
    Check dated 2026-01-21T00:39:27.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    Revision from v3.3.3 to v3.3.4 appears as a minor administrative update in the page footer; no study content or actions are affected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T01:44:22.000Z thumbnail image
  7. Check
    64 days ago
    Change Detected
    Summary
    Added a new Locations section with New York as a site; removed the New York Locations label and the HHS Vulnerability Disclosure link in this revision.
    Difference
    0.2%
    Check dated 2025-12-23T10:15:24.000Z thumbnail image

Stay in the know with updates to REOLYSIN in KRAS Mutant CRC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the REOLYSIN in KRAS Mutant CRC Clinical Trial page.